Dr Martens grew too fast after its IPO — and lost 80% of its value

Dr Martens listed on the London Stock Exchange in January 2021 at 370p per share, valuing the company at £3.7 billion. The IPO gave the brand a global platform and ambitious growth targets. Management pushed aggressively into the US market, expanding wholesale distribution and opening new stores. But the expansion was executed poorly — the company misread US demand, built up excess inventory, and had to resort to heavy discounting to clear stock.

The discounting eroded the brand's premium positioning and margins. Revenue fell from £1 billion in FY2023 to £877 million in FY2024 (down 12.3%), and pre-tax profit collapsed 41.7% to £93 million. The next year was worse — sales fell further to £765 million and pre-tax profit plunged to around £28 million, a 69% decline. Dr Martens issued five profit warnings in total. The stock, which had been priced at 370p at IPO, lost more than 80% of its value.

CEO Kenny Wilson, who had led the company for six years, stepped down in 2024 and was replaced by chief brand officer Ije Nwokorie in January 2025. The new CEO's strategy focused on tightening discount control, cutting costs, and restoring the brand's premium image. By 2026, Dr Martens reported a return to profit growth after reducing promotions. But the damage was lasting: the company that had been worth £3.7 billion at IPO was now valued at a fraction of that, and the brand's rebellious cachet — carefully cultivated over 60 years — had been eroded by years of discounting.

Dr Martens pushed US growth after its IPO, misread demand, and discounted to clear stock, eroding brand cachet and losing 80% of its value.

Dr Martens' aggressive US expansion post-IPO created excess inventory that forced heavy discounting, eroding the brand's premium positioning.

The company misread US consumer demand and wholesale channel dynamics, leading to inventory bottlenecks and a 28% drop in wholesale revenue.

Management prioritized volume growth over brand health, issuing five profit warnings as the strategy unraveled.

The brand's rebellious cachet was built over 60 years, but years of discounting and over-distribution eroded it in less than three.

A cult brand that goes public faces pressure to grow that can destroy its exclusivity. Dr Martens' IPO pushed management into a US expansion that eroded the brand through discounting.

Dr Martens replaced CEO Kenny Wilson in 2024 with Ije Nwokorie, who took over in January 2025. The new strategy focused on reducing discounting, controlling product distribution, and restoring the brand's premium image. By May 2026, the company reported a return to profit growth after tightening promotions. But the stock that had been worth £3.7 billion at IPO in 2021 had lost over 80% of its value. The brand's 60-year-old rebellious cachet, carefully maintained through limited distribution and cultural positioning, had been eroded by three years of aggressive expansion and discounting.